Point of care test for measurement of therapeutic drug levels
AssigneePfizer Inc.
InventorsVahe Bedian, Stafford McLean, Ronald S. Obach, Holly D. Soares
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of determining the proper dosage of Compound 122 (and other drugs that are metabolized by cytochrome P450 2D6) to be given to a patient. Also provided are methods of determining the metabolizer status of persons, devices for performing the invention methods, and antibodies for use in these devices and methods.
Claims20
A method for determining whether a person is a poor metabolizer or an extensive metabolizer of Compound 122, said method comprising the steps of:
- a) administering a test dosage of Compound 122 to said person;
- b) measuring the concentration of Compound 122 in a saliva sample from said person at a predetermined time period after said administration step;
- and
- c) classifying said person as a poor metabolizer or an extensive metabolizer of Compound 122 based upon the concentration of Compound 122 as measured in said measuring step.
A method for determining the proper dose of Compound 122 to be given to a patient, said method comprising the steps of:
- a) administering a test dosage of Compound 122 to said patient;
- b) measuring the concentration of Compound 122 in a saliva sample from said patient at a predetermined time period after said administration step;
- and
- c) determining that said patient requires a low dosage treatment of Compound 122 if said saliva concentration is high, and that said patient requires a standard dosage treatment of Compound 122 if said saliva concentration is low.
A device for measuring the salivary concentration of Compound 122, said device comprising:
- a) a lateral flow membrane;
- b) a saliva application zone on said membrane;
- and
- c) an indicator zone on said membrane spaced laterally from said saliva application zone;
- wherein immobilized in said indicator zone is an antibody specific for Compound 122, which antibody is labeled in a manner that provides an easily read color change if saliva applied to said saliva application zone contains an adequate concentration of Compound 122.
An antibody that specifically binds to Compound 122 wherein said antibody does not specifically bind to naturally occurring metabolites of Compound 122.
Dependencies are inferred from the claim text.